Evidence map›Paper›PMID 42851907›Full record

ReviewFrontiers in bioengineering and biotechnology2026

Surface marker-defined functional subpopulations of mesenchymal stromal cells: mechanisms, applications, and clinical translation.

Shuang Wu, Shengmeng Yuan, Jiting Li, Wenqi Sun, Fangjun Huo, Lei Liu, Chao Yang, Weidong Tian

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuang WuDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.
Shengmeng YuanDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.
Jiting LiDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.
Wenqi SunDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.
Fangjun HuoDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.
Lei LiuDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.
Chao YangChengdu Shiliankangjian Biotechnology Co., Ltd., Chengdu, Sichuan, China.
Weidong TianDepartment of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University Chengdu, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cells (MSCs) hold considerable promise in tissue regeneration due to their multilineage differentiation, paracrine signaling, and immunomodulatory capabilities, as evidenced by thousands of clinical trials. However, clinical translation is constrained by inconsistent and unpredictable efficacy. This primarily stems from MSC heterogeneity, including differences in tissue origin, functional subpopulations, donor age and disease status, and phenotypic drift and functional decline during

Indexed as

cell sortingfunctional markersmesenchymal stem cellssubpopulation heterogeneitytissue regeneration

Identifiers

PMID42851907
PMCPMC13647458

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.